AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of "Buy" from Analysts

Last updated on Saturday, June 19, 2021 | 2021 MarketBeat

AtriCure, Inc. (NASDAQ:ATRC) has earned a consensus rating of "Buy" from the nine research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $86.25.

ATRC has been the topic of a number of analyst reports. SVB Leerink upped their price objective on AtriCure from $78.00 to $95.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 26th. Stifel Nicolaus upped their price objective on AtriCure from $72.00 to $85.00 and gave the stock a "buy" rating in a research note on Tuesday. JPMorgan Chase & Co. upped their price objective on AtriCure from $70.00 to $81.00 and gave the stock an "overweight" rating in a research note on Friday, May 14th. Oppenheimer upped their price objective on AtriCure from $65.00 to $75.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 28th. Finally, Zacks Investment Research cut AtriCure from a "buy" rating to a "hold" rating in a research note on Friday, April 30th.

In related news, Director Sven Wehrwein sold 10,000 shares of the business's stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $77.97, for a total transaction of $779,700.00. Following the transaction, the director now directly owns 12,686 shares of the company's stock, valued at approximately $989,127.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Scott William Drake sold 38,641 shares of the business's stock in a transaction that occurred on Friday, May 7th. The stock was sold at an average price of $77.90, for a total value of $3,010,133.90. Following the transaction, the director now directly owns 79,677 shares in the company, valued at $6,206,838.30. The disclosure for this sale can be found here. Insiders have sold a total of 60,480 shares of company stock worth $4,642,804 over the last three months. 3.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ATRC. Altshuler Shaham Ltd acquired a new position in AtriCure in the 1st quarter valued at $40,000. Harbor Investment Advisory LLC grew its holdings in AtriCure by 58.7% in the 1st quarter. Harbor Investment Advisory LLC now owns 646 shares of the medical device company's stock valued at $42,000 after buying an additional 239 shares in the last quarter. FORA Capital LLC acquired a new position in AtriCure in the 1st quarter valued at $53,000. First Horizon Advisors Inc. grew its holdings in AtriCure by 33.1% in the 4th quarter. First Horizon Advisors Inc. now owns 981 shares of the medical device company's stock valued at $54,000 after buying an additional 244 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. acquired a new position in AtriCure in the 1st quarter valued at $57,000. 97.26% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ ATRC opened at $74.54 on Friday. The company has a market cap of $3.40 billion, a PE ratio of -67.15 and a beta of 1.07. The company has a 50 day moving average price of $72.69. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.10 and a quick ratio of 4.48. AtriCure has a 52 week low of $34.04 and a 52 week high of $80.44.

AtriCure (NASDAQ:ATRC) last released its earnings results on Monday, April 26th. The medical device company reported ($0.38) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.38). The firm had revenue of $59.28 million for the quarter, compared to analysts' expectations of $56.24 million. AtriCure had a negative return on equity of 10.49% and a negative net margin of 22.89%. Sell-side analysts forecast that AtriCure will post -1.15 earnings per share for the current fiscal year.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

See Also: How does a reverse stock split work?

Analyst Recommendations for AtriCure (NASDAQ:ATRC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: How to Track your Portfolio in Google Finance


7 Sports Betting Stocks That Will Shine Beyond March Madness

One of the many consequences of the novel coronavirus was the shutdown of live sports. For sports-minded individuals, one of the events that were missed the most was the NCAA Basketball Tournament affectionately known as March Madness.

But in addition to missing the entertainment that sports provide, cities and states realized, if they didn’t already, that sports are an economic necessity.

Live sports may also be a key to their post-pandemic future. But this goes beyond hotels and restaurants.

Sports betting has become big business. Currently, 25 states and the District of Columbia have legalized sports betting either by statute or by ballot initiative. That list is likely to grow. Many states face budget deficits and want to legalize sports betting for the revenue that it could receive.

And this is about more than allowing gamblers to place bets via a sportsbook in a casino. The real driver for this is mobile sports betting. According to the American Gaming Association, over 47 million people are expected to place bets during the NCAA basketball tournament, with approximately one-third of those bets (17.8 million) being placed online.

To help you take advantage of this still-emerging trend, we’ve put together this special presentation. Here we’ll highlight seven sports betting stocks that should generate significant revenue during March Madness and beyond.

View the "7 Sports Betting Stocks That Will Shine Beyond March Madness".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.